Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06842823 · ClinicalTrials.gov registry record · Phase 3
A Study of Navenibart in Participants With Hereditary Angioedema
A Phase 3 study of Hereditary Angioedema (HAE), sponsored by Astria Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 145
- Enrollment target
- 20
- Study locations
NCT06842823: Recruiting Phase 3 study of Hereditary Angioedema (HAE), sponsored by Astria Therapeutics.
NCT06842823 is a Phase 3 study of Hereditary Angioedema (HAE) that is actively recruiting participants, run by Astria Therapeutics. The registered enrollment target is 145 participants, above the 47-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (209% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06842823, a Phase 3 study of Hereditary Angioedema (HAE), is actively recruiting participants, sponsored by Astria Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 145 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG navenibart
Study Locations (20)
California
- Site 26 - San Diego
- Site 14 - San Diego
- Site 4 - Santa Monica
- Site 1 - Walnut Creek
Colorado
- Site 8 - Centennial
- Site 11 - Colorado Springs
Florida
- Site 25 - Tampa
- Site 69 - Weston
Ohio
- Site 7 - Cincinnati
- Site 12 - Toledo
Alabama
- Site 9 - Birmingham
Arizona
- Site 2 - Scottsdale
Arkansas
- Site 3 - Little Rock
Kansas
- Site 43 - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
What NCT06842823 shows while recruiting
NCT06842823 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, above the 47-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (209% higher).
The record links to 1 condition, with Hereditary Angioedema (HAE) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06842823 names 20 study sites across 14 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT06842823 about?
NCT06842823 is a clinical study titled "A Study of Navenibart in Participants With Hereditary Angioedema". This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to eva...
What is the current status of trial NCT06842823?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 145 participants. The study started on 2025-03-20. Estimated completion is 2027-09.
What conditions does trial NCT06842823 study?
This clinical trial studies the following conditions: Hereditary Angioedema (HAE).
What interventions are being tested in trial NCT06842823?
The interventions under investigation include: Placebo (DRUG), navenibart (DRUG).
Who is sponsoring clinical trial NCT06842823?
This trial is sponsored by Astria Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06842823 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema (HAE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
RECRUITING · Phase 3
-
Donidalorsen Treatment in Children With Hereditary Angioedema
RECRUITING · Phase 3
-
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
COMPLETED · Phase 3
-
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
RECRUITING · Phase 1
-
A Phase 2 in Adult Subjects With Hereditary Angioedema
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI